ETANA AND KPCDI PROVIDE HEALTH EDUCATION: IMPACT AND TREATMENT of ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Jakarta, 4 March 2023 - PT Etana Biotechnologies Indonesia (Etana) together with the Indonesian Dialysis Patient Community (KPCDI) held an online health education themed "Anemia in Chronic Kidney Patients: What are the Impacts and Treatments" with speaker dr. Elizabeth Yasmine Wardoyo, Sp.PD-KGH from Fatmawati Hospital, Jakarta. This webinar was held as a series of commemorations of World Kidney Day which falls on March 9, 2023. Etana and KPDCI have been consistently providing education to patients and the public regarding kidney health.
Randy Stevian, Head of Sales & Marketing of PT Etana Biotechnologies Indonesia said "Etana as one of the health companies in Indonesia routinely supports World Kidney Day activities every year, this is a form of our concern for patients with kidney disease, especially patients undergoing hemodialysis. We hope that this activity can provide appropriate information and education so that it can be used by patients and their families in getting even better therapy so that they can improve their quality of life and can return to normal life as usual."
Tony Richard Samosir, Chairman of KPCDI said “Through this health education, KPCDI wants to increase the knowledge of the dialysis patients so that they can choose the right therapy for themselves. This webinar aims to enable patients and companions to get good education, as we all know anemia is a condition in which the level of hemoglobin (HB/red blood cells) is less than normal and this can even cause oxygen transfer to the body to be disrupted. Anemia is also associated with chronic kidney disease with permanent damage to the kidneys which can no longer optimally produce the hormone erythropoietin (EPO). Through this webinar, we will hear speakers explain how to minimize anemia and keep our HB stable."
dr. Elizabeth Yasmine Wardoyo, Sp.PD-KGH said "Anemia in patients with kidney failure is caused by various factors, furthermore anemia also has an impact on patient morbidity and quality of life. Therefore, patients with kidney failure need to be treated for anemia by administering Ertythropoiesis Stimulating Agent (ESA) which can slow the progression, reduce morbidity and mortality and improve quality of life. ESA can be given to patients with kidney failure with the indicator of Hb <10 g/dL with certain conditions that must be met, such as absence of severe infection."
Epo injections must be done routinely, the problem is that in Indonesia the provision of erythropoietin has not been included in the hemodialysis financing, so the provision of blood transfusions is still quite a lot. Even though that blood transfusions have many risks when performed on dialysis patients. While EPO therapy is safer to undertake because it can produce a continuous increase in Hb, produce red blood cells that function normally, and can improve quality of life by maintaining a higher Hb target.
Etana at a glance
Founded in 2014, Etana is an Indonesian biopharmaceutical company that is researching,
producing, and marketing biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.
Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry, and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Ethane is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms.